CD274 and non-small cell lung carcinoma: In this pooled analysis, we retrospectively evaluated outcomes in patients with PD-L1–positive NSCLC, with or without known baseline brain metastases, who were treated with pembrolizumab monotherapy in KEYNOTE-001 and either pembrolizumab monotherapy or chemotherapy in KEYNOTE-010, -024, and -042.